Author:
Cardoso F.,Senkus E.,Costa A.,Papadopoulos E.,Aapro M.,André F.,Harbeck N.,Aguilar Lopez B.,Barrios C.H.,Bergh J.,Biganzoli L.,Boers-Doets C.B.,Cardoso M.J.,Carey L.A.,Cortés J.,Curigliano G.,Diéras V.,El Saghir N.S.,Eniu A.,Fallowfield L.,Francis P.A.,Gelmon K.,Johnston S.R.D.,Kaufman B.,Koppikar S.,Krop I.E.,Mayer M.,Nakigudde G.,Offersen B.V.,Ohno S.,Pagani O.,Paluch-Shimon S.,Penault-Llorca F.,Prat A.,Rugo H.S.,Sledge G.W.,Spence D.,Thomssen C.,Vorobiof D.A.,Xu B.,Norton L.,Winer E.P.
Reference74 articles.
1. ESO-ESMO 2nd International Consensus Guidelines for Advanced Breast Cancer (ABC2). Simultaneous publication in;Cardoso;Breast,2014
2. Global analysis of advanced/metastatic breast cancer: decade report (2005–2015);Cardoso;Breast,2018
3. N Howlader, AM Noone, M Krapcho et al (eds). SEER Cancer Statistics Review, 1975–2013. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2013/, based on November 2015 SEER data submission, posted to the SEER web site, April 2016.
4. Improved survival in metastatic breast cancer 1985–2016;Sundquist;Breast,2017
5. Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer;Kobayashi;Surg Today,2016